EVALUATION OF THE OSTEOSARCOMA CHEMOTHERAPY REGIMENS AND ITS TREATMENT RESULTS IN MESHED OMID HOSPITAL

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SALEK R.; GHAVAM NASIRI M.R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Avicenna Journal of Clinical Medicine Year:2004 | Volume:11 | Issue:3 (SN 33) Page(s): 5-11

Download Full-Text

Persian Verion

View:

1,488

Download:

Cites:

Information Journal Paper

Title

EVALUATION OF THE OSTEOSARCOMA CHEMOTHERAPY REGIMENS AND ITS TREATMENT RESULTS IN MESHED OMID HOSPITAL

Author(s)

SALEK R. | GHAVAM NASIRI M.R. | Issue Writer Certificate

Keywords

CHEMOTHERAPYQ3

ADJUVANTQ3

NEOADJUVANT THERAPYQ3

OSTEOSARCOMAQ3

Abstract

This study was designed to evaluate results of neoadjuvant and ADJUVANT CHEMOTHERAPY for nonmetastatic OSTEOSARCOMA patients. Forty four patients who were referred to Omid hospital from 1994 to 1999 were eligible to the study. For comparison based on different CHEMOTHERAPY regimens which had been prescribed, all patients were classified into 3 different subgroups named as HDMTX (including high dose methotrexate and other drugs based on a protocol known as T10), 3 drugs (low dose methotrexate, vincristine and cyclophosphamide) and 4 drugs (low to intermediate dose methotrexate, vincristine, cyclophosphamide and adriamycine) regimens. While 2 and 5 years Relapse Free Survival (RFS) were 45% and 28% respectively, there was not any significant statistical difference between the groups. In addition Median Event Free Survival (MEFS) was 18.5 months and again there was not any significant statistical difference between groups (15.5 months for HDMTX, 21 months for 3 drugs and 24 months for 4 drugs regimens). Considering as a prognostic factor, effects of adriamycin prescription, neoadjuvant CHEMOTHERAPY and adequacy of CHEMOTHERAPY courses in MEFS were evaluated. Putting Adriamycin into regimen and adequacy of CHEMOTHERAPY courses had a significant effect on MEFS improvement but neoajuvant CHEMOTHERAPY didn't have such a significant effect.As methotrexate was integrated into all different regimen however with different doses the study didn't show improving MEFS with increasing doses of this drug.

Cites

No record.

References

No record.

Cite

APA: Copy

SALEK, R., & GHAVAM NASIRI, M.R.. (2004). EVALUATION OF THE OSTEOSARCOMA CHEMOTHERAPY REGIMENS AND ITS TREATMENT RESULTS IN MESHED OMID HOSPITAL . AVICENNA JOURNAL OF CLINICAL MEDICINE (SCIENTIFIC JOURNAL OF HAMADAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES), 11(3 (SN 33)), 5-11. SID. https://sid.ir/paper/17742/en

Vancouver: Copy

SALEK R., GHAVAM NASIRI M.R.. EVALUATION OF THE OSTEOSARCOMA CHEMOTHERAPY REGIMENS AND ITS TREATMENT RESULTS IN MESHED OMID HOSPITAL . AVICENNA JOURNAL OF CLINICAL MEDICINE (SCIENTIFIC JOURNAL OF HAMADAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES)[Internet]. 2004;11(3 (SN 33)):5-11. Available from: https://sid.ir/paper/17742/en

IEEE: Copy

R. SALEK, and M.R. GHAVAM NASIRI, “EVALUATION OF THE OSTEOSARCOMA CHEMOTHERAPY REGIMENS AND ITS TREATMENT RESULTS IN MESHED OMID HOSPITAL ,” AVICENNA JOURNAL OF CLINICAL MEDICINE (SCIENTIFIC JOURNAL OF HAMADAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES), vol. 11, no. 3 (SN 33), pp. 5–11, 2004, [Online]. Available: https://sid.ir/paper/17742/en

Related Journal Papers